bivamelagon
Small molecule
Also known as LB54640
Evidence outlook · lead readout
NCT06046443 · Hypothalamic Obesity
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT06046443: This was a randomized, triple-blind, placebo-controlled Phase 2 trial in 28 participants with hypothalamic obesity. All three LB54640 doses produced a statistically significant reduction in BMI at 14 weeks compared with placebo, for example the highest dose: -9.3% vs +2.2% with placebo, p=0.0004, meeting the trial primary comparison, though the very small number of participants limits how confidently this result generalizes.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported from a conference presentation covering 96 participants, fewer than the trial's registered enrollment; the source does not cite the trial's registry number. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06046443 NCT06046443 · Hypothalamic Obesity This was a randomized, triple-blind, placebo-controlled Phase 2 trial in 28 participants with hypothalamic obesity. All three LB54640 doses produced a statistically significant reduction in BMI at 14 weeks compared with placebo, for example the highest dose: -9.3% vs +2.2% with placebo, p=0.0004, meeting the trial primary comparison, though the very small number of participants limits how confidently this result generalizes. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT06046443 | 2 | Mean percentage change in BMI (From Baseline to Week 14) 2026-02-09 | Mean % change in BMI at Week 14: 600mg -9.3% (p=0.0004), 400mg -7.7% (p=0.0002), 200mg -2.7% (p=0.0180), placebo +2.2% | Partial signal | link ↗ |
View 1 more trial
NCT07156578 NCT07156578 · Hypothalamic Obesity Registry: NCT07156578 | 2 | Safety and tolerability of bivamelagon as assessed by the number and frequency of AEs (Baseline to up to 2 years) 2028-04-15 | In progress: results expected 15 Apr 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other MC4R drugs
setmelanotide, bremelanotide, RM-718. Compare all 4 MC4R drugs
3 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Hypothalamic Obesity: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Bivamelagon: this drug | Phase 2 | Small molecule | MC4R | Partial signal | NCT06046443: Mean % change in BMI at Week 14: 600mg -9.3% (p=0.0004), 400mg -7.7% (p=0.0002), 200mg -2.7% (p=0.0180), placebo +2.2% | |
| Setmelanotide (Imcivree) | Approved | Peptide | MC4R | Reliable signal | NCT05774756: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984) | |
| Bremelanotide (Vyleesi) | Phase 2(overall; approved for another use) | Peptide | MC4R | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| RM-718 | Phase 1/2(overall) | Peptide | MC4R | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow bivamelagon to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.